TITLE

AUSSIE DMT BAN

PUB. DATE
August 2012
SOURCE
American Herb Association Quarterly Newsletter;Summer2012, Vol. 27 Issue 3, pp14
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that the Australian Therapeutic Goods Administration has withdrawn a potential ban in May 2012 on the use of entheogenic plants containing dimethyltryptamine (DMT) by religions and native people.
ACCESSION #
79564875

 

Related Articles

  • Safety through reporting. Weekes, Lynn M. // Medical Journal of Australia;3/2/2015, Vol. 202 Issue 4, p168 

    The article reports on the development of two online learning modules by NPS MedicineWise and the Therapeutic Goods Administration (TGA) to support health professionals to report adverse events associated with therapeutic products.

  • Regulatory Action and News.  // WHO Drug Information;2010, Vol. 24 Issue 1, p33 

    The article presents international drug regulation news briefs. The European Medicines Agency has created a new organizational structure to strengthen the lifecycle-management of medicines. In Australia the Therapeutic Goods Administration (TGA) adopted the European Guideline on Risk Management...

  • Heparin alert in Australia.  // Australian Nursing Journal;May2008, Vol. 15 Issue 10, p5 

    The article focuses on an advisory from the Australian Therapeutic Goods Administration (TGA) that heparin should only be used where medically essential and if patients are monitored carefully. This advice reportedly came after numerous deaths from contamination in drug supplies have been...

  • Australia Warns of Tainted Batches of Heparin. Scott, Alex // Chemical Week;4/7/2008, Vol. 170 Issue 11, p24 

    This article reports on a warning issued by authorities in Australia in 2008 that four batches of blood-thinning drug heparin from AstraZeneca are contaminated. The Therapeutic Goods Administration has advised doctors to use heparin only where it is medically essential until more information is...

  • Influenza virus vaccines for 2006-2007 northern hemisphere.  // WHO Drug Information;2006, Vol. 20 Issue 3, p196 

    The article focuses on flu vaccines listed by the World Health Organization (WHO) to be distributed in the Northern Hemisphere from 2006 to 2007. The vaccines listed for types of influenza included an A(H1N1) or New Caledonia virus, an A(H3N2) or Wisconsin virus, and a B or Malaysia virus. A...

  • Enoxaparin contamination: batches recalled.  // WHO Drug Information;2008, Vol. 22 Issue 2, p109 

    The article reports on the recall of batches of the anticoagulant medicine enoxaparin by the Therapeutic Goods Administration (TGA) in Australia and by the Medical Products Agency in Sweden. It states that TGA has recalled five batches of enoxaparin in Australia due to the detection of an...

  • Australian Adverse Drug Reaction Committee (ADRAC) to be replaced.  // WHO Drug Information;2008, Vol. 22 Issue 4, p297 

    The article reports on the replacement of the Australian Adverse Drug Reaction Committee (ADRAC), a subcommittee of the Australian Drug Evaluation Committee (ADEC), by a Medicines Safety Committee as part of the reform of the Therapeutic Goods Administration (TGA) on pharmacovigilance for...

  • Imalux imaging system gets approval for down under. Stroope, Leslie // Crain's Cleveland Business;9/11/2006, Vol. 27 Issue 37, p20 

    The article reports that the Therapeutic Goods Administration of Australia and New Zealand has given Imalux Corp. the approval to market its Niris imaging system in their countries. The medical imaging system uses near-infrared light to create images of human tissue. The system would be...

  • Evaluating and prescribing new medicines in general practice. Thistlethwaite, Jill; Weeks, Lynn // Australian Journal of General Practice;Jun2018, Vol. 47 Issue 6, p327 

    Background In Australia, the Therapeutic Goods Administration (TGA) approves new medicines that general practitioners (GPs) may prescribe. Medicines listed under the Pharmaceutical Benefits Scheme (PBS) have undergone a rigorous independent evaluation in relation to comparative efficacy, safety...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics